https://www.selleckchem.com/products/reacp53.html
These results demonstrate that adjuvanted spike protein subunit vaccine is a viable strategy for rapidly eliciting SARS-CoV-2 neutralizing antibodies and CD4 T cell responses of various qualities depending on the adjuvant used, which can be explored in further vaccine development against COVID-19. This work was supported by the European Union Horizon 2020 research and innovation program under grant agreement no. 101003653. This work was supported by the European Union Horizon 2020 research and innovation program under grant agreement no
Like
Comment
Share
